Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Sponsor: Alaunos Therapeutics
Summary
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.
Official title: Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2022-04-04
Completion Date
2023-10-11
Last Updated
2026-11-09
Healthy Volunteers
No
Conditions
Interventions
Neoantigen specific TCR-T cell drug product
Phase I: Ascending dose, single Infusion of TCR+ Cells Phase II: Single infusion at the RP2D
Aldesleukin (IL-2)
To support growth and activation of TCR-T cell drug product
Locations (1)
MD Anderson Cancer Center
Houston, Texas, United States